middle.news
BlinkLab Secures $7.66M to Fast-Track FDA Trials for Autism and ADHD Diagnostics
3:36am on Monday 2nd of June, 2025 AEST
•
Healthcare
Read Story
BlinkLab Secures $7.66M to Fast-Track FDA Trials for Autism and ADHD Diagnostics
3:36am on Monday 2nd of June, 2025 AEST
Key Points
Placement raised A$7.66M at A$0.30 per share
Funds to accelerate FDA trials for autism (Dx1) and initiate ADHD (Dx2) regulatory study
Board and management committed A$210,000 subject to shareholder approval
Capital to support European CE and MDR approvals and expand patent portfolio
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Blinklab (ASX:BB1)
OPEN ARTICLE